CAMBRIDGE, Mass. – ConcertAI, a leader in oncology-focused generative and agentic AI SaaS and multi-modal data solutions for healthcare and life sciences, announced the appointment of Dr. Shaalan Beg as Chief Medical Officer, Oncology.
In his new role, Dr. Beg will lead efforts to expand and engage the CancerLinQ community, ensuring that the perspectives of practicing oncologists and their patients directly inform product development and innovation across ConcertAI’s portfolio. He will also act as a key liaison between clinicians and ConcertAI’s software and data teams, fostering stronger collaboration and advancing patient-centered solutions.
“Dr. Beg’s extensive experience working with the American Society of Clinical Oncology and real-world data platforms positions him uniquely to further strengthen our clinical partnerships and help shape our strategy as we continue to scale,” said Eron Kelly, Chief Executive Officer of ConcertAI. “As a strategic connector between the CancerLinQ oncologist community and our internal software and product teams, he’ll be crucial in ensuring that clinical insights and patient-centered innovation remain at the heart of our technology solutions.”
Dr. Beg is a nationally recognized medical oncologist and healthcare leader with deep expertise in gastrointestinal cancers, clinical research, and oncology informatics. He previously served as Senior Advisor for Clinical Research at the National Cancer Institute, where he contributed to national initiatives in clinical trial modernization, public-private partnerships, and digital health innovation. His career spans academia, government, and industry, including leadership roles at UT Southwestern Medical Center and Science37.
His research has been published in leading journals such as The New England Journal of Medicine, JAMA Oncology, and the Journal of Clinical Oncology. Dr. Beg has also advised major initiatives including the Bloomberg International Cancer Coalition, the White House Cancer Moonshot, CancerX, the Coalition for Healthcare AI, and the Association of Community Cancer Centers (ACCC) Community Oncology Research Institute. He is a Fellow of the American Society of Clinical Oncology.
“Having spent my career translating innovation into meaningful clinical impact, I’m looking forward to joining ConcertAI to ensure artificial intelligence continues improving cancer care and clinical research,” said Dr. Beg. “As a practicing oncologist, I’m acutely aware of the challenges faced by life science organizations in developing new treatments, diagnostics, and devices—as well as the needs of healthcare providers—and I’m excited to put this knowledge into action with the ConcertAI team.”
